# A Study of MT-0551 in Patients With Systemic Sclerosis

> **NCT05198557** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tanabe Pharma Corporation** · enrollment: 80 (estimated)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Inebilizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05198557
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-20
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198557, "A Study of MT-0551 in Patients With Systemic Sclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05198557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*